|
|
Volumn 23, Issue 8, 2005, Pages 906-
|
|
Next-generation monoclonals less profitable than trailblazers?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABCIXIMAB;
ADALIMUMAB;
ALEMTUZUMAB;
BASILIXIMAB;
BEVACIZUMAB;
CEDELIZUMAB;
CETUXIMAB;
DACLIZUMAB;
EFALIZUMAB;
GEMTUZUMAB OZOGAMICIN;
IBRITUMOMAB TIUXETAN;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
OMALIZUMAB;
ORTHOCLONE;
PALIVIZUMAB;
RITUXIMAB;
TOSITUMOMAB I 131;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ANTIBODY PRODUCTION;
BIOEQUIVALENCE;
BIOTECHNOLOGY;
DRUG MARKETING;
NOTE;
ONCOLOGY;
PRIORITY JOURNAL;
PROFIT;
ANTIBODIES, MONOCLONAL;
DRUG INDUSTRY;
EUROPE;
IMMUNOTHERAPY;
INCOME;
UNITED STATES;
|
|
EID: 23444448006
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0805-906 Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|